Evaluation of the effect of calcium gluconate and bovine thrombin on the temporal release of transforming growth factor beta 1 and platelet-derived growth factor isoform BB from feline platelet concentrates

BMC Veterinary Research

Cleuza MF Rezende²  Jorge U Carmona¹  Catalina López¹  Diana L Ríos¹  María E Álvarez¹  Raul F Silva² 

[1] Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Caldas, Colombia;Departamento de Clinica e Cirurgia Veterinárias, Universidade Federal de Minas Gerais, Minas Gerais, Brazil

关键词: Regenerative medicine;    Platelet rich plasma;    Bovine thrombin;    Cat;    Calcium gluconate;   

Others  :  1119675
DOI  :  10.1186/1746-6148-8-212

 received in 2012-06-12, accepted in 2012-10-23,  发布年份 2012

【 摘 要 】

Background

There are not reported regarding the protocols for obtaining platelet concentrates (PC) in cats for medical purposes. The objectives of this study were: 1) to describe a manual method for producing two kinds of PC in cats (PC-A and PC-B), 2) to describe the cellular population of the PC, 3) to measure and compare the effect of calcium gluconate (CG) and bovine thrombin (BT) on the temporal release of transforming growth factor beta 1 (TGF-β₁) and platelet-derived growth factor type BB (PDGF-BB) at 3 and 12 hours post-activation and 4) to establish correlations between the cellular population of both PCs and the concentration of growth factors (GF). Blood samples were taken from 16 cats for complete blood count, plasma collection and PC preparation. The PC were arbitrarily divided into two fractions, specifically, PC-A (lower fraction) and PC-B (upper fraction).

Results

The platelet counts were significantly different (P<0.05) between the PC and whole blood but not between the PC fractions. The TGF-β₁ concentration efficiencies for PC-A and PC-B activated with CG were 42.86% and 46.54%, and activated with BT were 42.88% and 54.64%, respectively. The PDGF-BB concentration efficiencies for PC-A and PC-B activated with CG were 61.36% and 60.61%, and activated with BT were 65.64% and 72.12%, respectively. The temporal release of GFs showed no statistically significant difference (P>0.05) between the activating substances at the time or for any PC fraction.

Conclusions

Whatever the activation means, these preparations of cat PC provide significant concentrations of platelets and GFs for possible clinical or experimental use.

【 授权许可】

   
2012 Silva et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Carmona JU, Lopéz C, Sandoval J: Review of the currently available system to obtain platelet related products to treat equine musculoskeletal injuries. Rec Pat Regen Med 2012, 3:1.
• [2]Carmona JU, Argüelles D, Climent F, Prades M: Autologous platelet concentrates as a treatment of horses with osteoarthritis: a preliminary pilot clinical study. J Equine Vet Sci 2007, 27(4):167-170.
• [3]Georg R, Maria C, Gisela A, Bianca C: Autologous conditioned plasma as therapy of tendon and ligament lesions in seven horses. J Vet Sci 2010, 11(2):173-175.
• [4]Bosch G, René Van Weeren P, Barneveld A, van Schie HT: Computerised analysis of standardised ultrasonographic images to monitor the repair of surgically created core lesions in equine superficial digital flexor tendons following treatment with intratendinous platelet rich plasma or placebo. Vet J 2011, 187(1):92-98.
• [5]Monteiro SO, Lepage OM, Theoret CL: Effects of platelet-rich plasma on the repair of wounds on the distal aspect of the forelimb in horses. Am J Vet Res 2009, 70(2):277-282.
• [6]You TM, Choi BH, Li J, Jung JH, Lee HJ, Lee SH, Jeong SM: The effect of platelet-rich plasma on bone healing around implants placed in bone defects treated with Bio-oss: a pilot study in the dog tibia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103(4):8-12.
• [7]Dutra CEA, Pereira MM, Serakides R, Rezende MCF: In vivo evaluation of bioactive glass foams associated with platelet-rich plasma in bone defects. J Tissue Eng Regen Med 2008, 2(4):221-227.
• [8]Casati MZ, Vasconcelos-Gurgel BC, Gonçalves PF, Pimentel SP, Rocha-nogueira G, Nociti JRFH, Sallum EA: Platelet-rich plasma does not improve bone regeneration around peri-implant bone defects – a pilot study in dogs. Int J Oral Maxillofac Surg 2007, 36(2):132-136.
• [9]Appel TR, Pötzsch B, Müller J, von Lindern JJ, Bergé SJ, Reich RH: Comparison of three different preparations of platelet concentrates for growth factor enrichment. Clin Oral Implants Res 2002, 13(5):522-528.
• [10]Beldon P: Basic Science of wound healing. Surgery 2010, 28(9):409-412.
• [11]Roberts DE, Archibald MN, Ratna B: Mechanism of collagen activation in human platelets. J Biol Chem 2004, 279(9):19421-19430.
• [12]Bergmeier W, Stefanini L: Novel molecules in calcium signaling in platelets. J Thromb Haemost 2009, 7(S1):187-190.
• [13]Jennings LK: Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009, 102(2):248-257.
• [14]Khan ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999, 103(6):879-887.
• [15]Chandler JC, Beale BS: Feline Orthopedics. Clin Tech Small Anim Prac 2002, 17(4):190-203.
• [16]Sánchez M, Azofra J, Anitua E, Andía I, Padilla S, Santisteban J, Mujika I: Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc 2003, 35(10):1648-1652.
• [17]Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J: Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology 2007, 114(7):1286-1293.
• [18]Thor A, Franke-Stenport V, Johansson CB, Rasmusson L: Early bone formation in humans bone grafts treated with platelet-rich plasma: preliminary histomorphometric results. Int J Oral Maxillofac Surg 2007, 36(12):1164-1171.
• [19]Greppi N, Mazzucco L, Galetti G, Bona F, Petrillo E, Smacchia C, Raspollini E, Cossovich P, Caprioli R, Borzini P, Rebulla P, Marconi M: Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. Biologicals 2011, 39(2):73-80.
• [20]Argüelles D, Carmona JU, Climent F, Muñoz E, Prades M: Autologous platelet concentrates as a treatment for musculoskeletal lesions in five horses. Vet Rec 2008, 162(7):208-211.
• [21]Waselau M, Sutter WW, Genovese RL, Bertone AL: Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in standardbred racehorses. J Am Vet Med Assoc 2008, 232(10):1515-1520.
• [22]Intini G: The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials 2009, 30(28):4956-4966.
• [23]Grossklaus CHR, Damerau B, Lemgo E, Vogt W: Induction of platelet aggregation by the complement-derived peptides C3a and C5a. Naunym-Schmiedeberg′s arch Pharmacol 1976, 295(1):71-76.
• [24]Burke SE, Dicola G, Lefer AM: Protection of ischemic cat myocardium by cgs-13080, a selective potent throboxane A2 synthesis inhibitor. J Cardiovas Pharmacol 1983, 5(5):842-847.
• [25]Burke SE, Lefer AM, Nicolaou KC, Smith GM: SMITH JB: Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Br J Pharmacol 1983, 78(2):287-292.
• [26]Hayes KG, Pronczuk A, Addesa AE, Stephan ZF: Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr 1989, 49(6):1211-1216.
• [27]Johnson G, Tsao PS, Mulloy D, Lefer AM: Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J Pharmacol Exp Ther 1990, 252(1):35-41.
• [28]Murohara T, Scalia R, Lefer AM: Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res 1996, 78(5):780-789.
• [29]Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM: Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999, 41(1):65-76.
• [30]Park JE, Barbul A: Understanding the role of immune regulation in wound healing. Am J Surg 2004, 187(5A):11S-16S.
• [31]Enoch S, Leaper DJ: Basic science of wound healing. Surgery 2008, 26(2):31-37.
• [32]Weibrich G, Kleis WK, Hitzler WE, Hafner G: Comparison of the platelet concentrate collection system with the plasma-rich-in growth factors kit to produce platelet rich plasma: a technical report. Inter J Oral Maxillofac Implants 2005, 20(1):118-123.
• [33]Argüelles D, Carmona JU, Pastor J, Iborra A, Viñals L, Martínes P, Bach E, Prades M: Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci 2006, 81(2):237-245.
• [34]Choi BH, Zhu SJ, Kim BJ, Huh JY, Lee SH, Jung JH: Effect of platelet rich-plasma (PRP) concentration on the viability and proliferation of alveolar bone cells: an in vitro study. Int J Oral Maxillofac Surg 2005, 34(4):420-424.
• [35]Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I: Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 2010, 14(1):28-32.
• [36]Boudreaux MK, Ebbe S: Comparison of platelet number, Mean platelet volume and platelet mass in five mammalian species. Comp Haematol Int 1998, 8(1):16-20.
• [37]Moritz A, Walcheck BK, Weiss DJ: Evaluation of flow cytometric and automated methods for detection of activated platelets in dogs with inflammatory disease. Am J Vet Res 2005, 66(2):325-329.
• [38]Marx RE: Platelet-rich plasma: evidence to support its usage. J Oral Maxillofac Surg 2004, 62(4):489-496.
• [39]Thoesen MS, Vanden Berg-Foels WS, Stokol T, Rassnick KM, Jacobson MS, Kevy SV, Todhunter RJ: Use of a centrifugation-based, point-of-care device for production of canine autologous bone marrow and platelet concentrates. Am J Vet Res 2006, 67(10)):1655-1661.
• [40]Kanthan SR, Kavitha G, Addi S, Choon DSK, Kamarul T: Platelet-rich plasma (PRP) enhaces bone healing in non-united critical-sized defects: a preliminary study involving rabbit models. Injury 2011, 42(8):782-789.
• [41]Fresno L, Fondevila D, Bambo O, Chacaltana A, García F, Andaluz A: Effects of platelet-rich plasma on intestinal wound healing in pigs. Vet J 2010, 185(3):322-327.
• [42]Anitua E, Andía I, Sanchez M, Azofra J, del Mar Zalduendo M, de la Fuente M, Nurden P, Nurden AT: Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res 2005, 23(2):281-286.
• [43]Boudreaux MK, Osborne CD, Herre AC, Rivera ER, Spangler EA: Unique structure of the M loop region of β1-tubulin may contribute to size variability of platelets in the family Felidae. Vet Clin Pathol 2010, 39(4):417-423.
• [44]Arata S, Ohmi A, Mizukoshi F, Baba K, Ohno K, Setoguchi A, Tsujimoto H: Urinary transforming growth factor-beta1 in feline chronic renal failure. J Vet Med Sci 2005, 67(12):1253-1255.
• [45]Sapan CV, Lundblad RL: Considerations regarding the use of blood samples in the proteomic identification of biomarkers for cancer diagnosis. Cancer Genomics Proteomics 2006, 3(3–4):227-230.
• [46]Van den Ouweland AM, Van Groningen JJ, Schalken JA, Van Neck HW, Bloemers HP, Van de Ven WJ: Genetic organization of the c-sis transcription unit. Nucleic Acids Res 1987, 15(3):959-970.
• [47]Donnelly BP, Nixon AJ, Haupt JL, Dahlgren LA: Nucleotide structure of equine platelet-derived growth factor-A and -B and expression in horses with induced acute tendinitis. Am J Vet Res 2006, 67(7):1218-1225.
• [48]Mazzucco L, Balbo V, Cattana E, Guascino R, Borzini P: Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: fibrinet, regenPRP-Kit, plateltex and one manual procedure. Vox Sang 2009, 97(2):110-118.
• [49]Mazzucco L, Balbo V, Cattana E, Borzini P: Platelet-rich plasma and platelet gel preparation using Plateltex. Vox Sang 2008, 94(3):202-208.
• [50]Fufa D, Shealy B, Jacobson M, Kevy S, Murray MM: Activation of platelet-rich plasma using soluble type I colagen. J Oral Maxillofac Surg 2008, 66(4):684-690.
• [51]Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH: Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001, 233(1):88-96.
• [52]Schoenecker JG, Johnson RK, Lesher AP, Day JD, Love SD, Hoffman MR, Ortel TL, Parker W, Lawson JH: Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001, 159(5):1957-1969.
• [53]Crovetti G, Martinelli G, Issi M, Barone M, Guizzardi M, Campanati B, Moroni M, Carabelli A: Platelet gel for healing cutaneous chronic wounds. Transfus Apher Sci 2004, 30(2):145-151.
• [54]DeRossi R, Coelho AC, Mello GS, Frazilio FO, Leal CR, Facco GG, Brum KB: Effects of platelet rich-plasma gel on skin healing in surgical wound in horses. Acta Cir Bras 2009, 24(4):276-281.
• [55]O'Brien M, Murphy MG, Lowe JA: Hematology and clinical chemistry parameters in the cat (Felis domesticus). J Nutr 1998, 128(12):2678S-2679S.
• [56]Weibrich G, Wilfried KGK, Rainer B, Hitzler WE, Hafner G: The Harvest Smart PRePTM system versus the Friadent-Schütze platelet-rich plasma kit. Clin Oral Implants Res 2003, 14(2):233-239.